Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$407.90 USD
-4.32 (-1.05%)
Updated Oct 15, 2025 04:00 PM ET
After-Market: $407.10 -0.80 (-0.20%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRTX 407.90 -4.32(-1.05%)
Will VRTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Other News for VRTX
VRTX's price rises by 1.19% on October 14, though its technical setup remains stable.
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
VRTX forms Non-ADX 1,2,3,4 Bullish on October 13
Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo
Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)